The Correlation Between the Subsets of Tumor Infiltrating Memory T Cells and the Expression of Indoleamine 2,3-Dioxygenase in Gastric Cancer

被引:35
|
作者
Zhang, Rupeng [1 ]
Liu, Hui [1 ]
Li, Fangxuan [2 ]
Li, Hui [3 ]
Yu, Jinpu [3 ]
Ren, Xiubao [3 ]
机构
[1] Tianjin Med Univ Canc Inst & Hosp, Dept Gastr Canc Surg, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Canc Prevent Ctr, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Dept Immunol, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
关键词
Tumor-infiltrating T cells; Indoleamine 2,3-dioxygenase; Memory T cells; Gastric cancer; PROTECTIVE IMMUNITY; ANTITUMOR IMMUNITY; COLORECTAL-CANCER; LYMPHOCYTES; MTOR; INHIBITION; DIFFERENTIATION; PROLIFERATION; SUPPRESSION; ACTIVATION;
D O I
10.1007/s10620-013-2837-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Although many researchers have concentrated on the mechanism of T cell anergy resulting from over-expression of Indoleamine 2,3-dioxygenase (IDO), it remains unclear what alterations will developed in memory T cells (Tm) under over-expression of IDO. Immunohistochemical staining for IDO expression in gastric cancer tissues (n = 50) was carried out. Tumor-infiltrating memory Tm cells were counted by flow cytometry. The association between IDO expression and the subsets of tumor infiltrating Tm are discussed. The higher IDO expressions were significantly associated with deeper invasion (P = 0.016) and higher frequencies (P = 0.038) of lymph node metastasis. The lower tumor-infiltrating CD4(+)Tm were significantly associated with the advanced clinical stage (P = 0.026) and lymph node metastasis (P = 0.016). The lower percentages of CD8(+)Tm were significantly related to undifferentiated histological type (P = 0.042) and lymph node metastasis (P = 0.037). However, the lower percentage of CD8(+)Tem was significantly correlated to differentiated histological type (P = 0.017), lower frequencies of lymph node metastasis (P = 0.014), and earlier clinical stage (P = 0.008). The higher IDO expression patients had significantly lower percentages of CD4(+)Tm (P = 0.012) and CD8(+)Tm (P = 0.033). Nevertheless, it was confirmed that the higher level of IDO expression correlated with higher percentages of CD8(+)Tm cells in univariate and multivariate analysis (P = 0.011). IDO over-expression and Tm in tumor microenvironments were correlated with the disease stage and histological type of gastric cancer. Higher IDO expression was related to the lower percentage of CD4(+)Tm and CD8(+)Tm, whereas the higher level of IDO expression related with a higher percentage of CD8(+)Tem.
引用
收藏
页码:3494 / 3502
页数:9
相关论文
共 50 条
  • [41] Detection of indoleamine 2,3-dioxygenase 1-expressing cells in canine normal and tumor tissues
    Ikeda, Namiko
    Kato, Daiki
    Tsuboi, Masaya
    Yoshitake, Ryohei
    Eto, Shotaro
    Yoshimoto, Sho
    Shinada, Masahiro
    Kamoto, Satoshi
    Hashimoto, Yuko
    Takahashi, Yousuke
    Chambers, James
    Uchida, Kazuyuki
    Nishimura, Ryohei
    Nakagawa, Takayuki
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2021, 83 (12) : 1885 - 1890
  • [42] Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment
    Schafer, Cara C.
    Wang, Yong
    Hough, Kenneth P.
    Sawant, Anandi
    Grant, Stefan C.
    Thannickal, Victor J.
    Zmijewski, Jaroslaw
    Ponnazhagan, Selvarangan
    Deshane, Jessy S.
    ONCOTARGET, 2016, 7 (46) : 75407 - 75424
  • [43] Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
    Ninomiya, Soranobu
    Narala, Neeharika
    Huye, Leslie
    Yagyu, Shigeki
    Savoldo, Barbara
    Dotti, Gianpietro
    Heslop, Helen E.
    Brenner, Malcolm K.
    Rooney, Cliona M.
    Ramos, Carlos A.
    BLOOD, 2015, 125 (25) : 3905 - 3916
  • [44] Inhibition of allogeneic T-cell response by Kupffer cells expressing indoleamine 2,3-dioxygenase
    Yan, Mao-Lin
    Wang, Yao-Dong
    Tian, Yi-Feng
    Lai, Zhi-De
    Yan, Lv-Nan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (05) : 636 - 640
  • [45] The Cystine/Glutamate Antiporter Regulates the Functional Expression of Indoleamine 2,3-Dioxygenase in Human Dendritic Cells
    D'Angelo, J. A.
    Mattox, M. L.
    Fiebiger, E.
    Dickinson, B. L.
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2012, 76 (04) : 448 - 449
  • [46] Indoleamine 2,3-dioxygenase 1 is highly expressed in glioma stem cells
    Ozawa, Yoshinari
    Yamamuro, Shun
    Sano, Emiko
    Tatsuoka, Juri
    Hanashima, Yuya
    Yoshimura, Sodai
    Sumi, Koichiro
    Hara, Hiroyuki
    Nakayama, Tomohiro
    Suzuki, Yutaka
    Yoshino, Atsuo
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 524 (03) : 723 - 729
  • [47] Vascular endothelial growth factor-A enhances indoleamine 2,3-dioxygenase expression by dendritic cells and subsequently impacts lymphocyte proliferation
    Marti, Luciana Cavalheiro
    Pavon, Lorena
    Severino, Patricia
    Sibov, Tatiana
    Guilhen, Daiane
    Moreira-Filho, Carlos Alberto
    MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2014, 109 (01): : 70 - 79
  • [48] Indoleamine-2,3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer
    Wen-Juan Ma
    Xing Wang
    Wen-Ting Yan
    Zhong-Guo Zhou
    Zhi-Zhong Pan
    Gong Chen
    Rong-Xin Zhang
    World Journal of Gastroenterology, 2018, (20) : 2181 - 2190
  • [49] Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment
    Gide, Tuba N.
    Allanson, Benjamin M.
    Menzies, Alexander M.
    Ferguson, Peter M.
    Madore, Jason
    Saw, Robyn P. M.
    Thompson, John F.
    Long, Georgina V.
    Wilmott, James S.
    Scolyer, Richard A.
    HISTOPATHOLOGY, 2019, 74 (06) : 817 - 828
  • [50] Immunological and Nonimmunological Effects of Indoleamine 2,3-Dioxygenase on Breast Tumor Growth and Spontaneous Metastasis Formation
    Levina, Vera
    Su, Yunyun
    Gorelik, Elieser
    CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2012,